215 related articles for article (PubMed ID: 10508010)
1. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
[TBL] [Abstract][Full Text] [Related]
2. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
3. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.
Mewshaw JP; Myrick FT; Wakefield DA; Hooper BJ; Harris JL; McCreedy B; Borroto-Esoda K
J Acquir Immune Defic Syndr; 2002 Jan; 29(1):11-20. PubMed ID: 11782585
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.
Furman PA; Jeffrey J; Kiefer LL; Feng JY; Anderson KS; Borroto-Esoda K; Hill E; Copeland WC; Chu CK; Sommadossi JP; Liberman I; Schinazi RF; Painter GR
Antimicrob Agents Chemother; 2001 Jan; 45(1):158-65. PubMed ID: 11120959
[TBL] [Abstract][Full Text] [Related]
5. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach.
Chong Y; Borroto-Esoda K; Furman PA; Schinazi RF; Chu CK
Antivir Chem Chemother; 2002 Mar; 13(2):115-28. PubMed ID: 12238529
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.
Narayanasamy J; Pullagurla MR; Sharon A; Wang J; Schinazi RF; Chu CK
Antiviral Res; 2007 Sep; 75(3):198-209. PubMed ID: 17532483
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.
Gu Z; Wainberg MA; Nguyen-Ba P; L'Heureux L; de Muys JM; Rando RF
Nucleosides Nucleotides; 1999; 18(4-5):891-2. PubMed ID: 10432704
[TBL] [Abstract][Full Text] [Related]
9. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
[TBL] [Abstract][Full Text] [Related]
10. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys.
Chen H; Schinazi RF; Rajagopalan P; Gao Z; Chu CK; McClure HM; Boudinot FD
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1625-30. PubMed ID: 10606085
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
13. Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.
Sharma PL; Nurpeisov V; Lee K; Skaggs S; Di San Filippo CA; Schinazi RF
Virology; 2004 Apr; 321(2):222-34. PubMed ID: 15051383
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.
Kewn S; Wang LH; Hoggard PG; Rousseau F; Hart R; MacNeela JP; Khoo SH; Back DJ
Antimicrob Agents Chemother; 2003 Jan; 47(1):255-61. PubMed ID: 12499199
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
16. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Tisdale M; Alnadaf T; Cousens D
Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
[TBL] [Abstract][Full Text] [Related]
17. High-performance liquid chromatographic determination of (-)-beta-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection.
Rajagopalan P; Gao Z; Chu CK; Schinazi RF; McClure HM; Boudinot FD
J Chromatogr B Biomed Appl; 1995 Oct; 672(1):119-24. PubMed ID: 8590923
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation and pharmacokinetics of prodrug 9-(beta-D-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(beta-D-1,3-dioxolan-4-yl)guanine in mice.
Manouilov KK; Manouilova LS; Boudinot FD; Schinazi RF; Chu CK
Antiviral Res; 1997 Aug; 35(3):187-93. PubMed ID: 9298758
[TBL] [Abstract][Full Text] [Related]
19. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
